| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-766 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-766
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-763
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-765 |
| filingDate |
2017-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2019-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-108261426-B |
| titleOfInvention |
Pharmaceutical compositions and their use in medicaments for the treatment of tumors and/or cancers |
| abstract |
The present invention provides pharmaceutical compositions and their use in medicines for the treatment of tumors and/or cancers. The active ingredients of the pharmaceutical composition include an oncolytic virus and NK cells, and the oncolytic virus can selectively replicate in tumor cells. The combined use of the oncolytic virus and NK cells in the present invention can produce a synergistic inhibitory effect on tumors and/or cancers. In addition, both oncolytic virus and NK cells have the characteristics of recognizing tumor cells and will not kill normal cells. The combined use of the two has significant advantages in safety and efficacy. |
| priorityDate |
2017-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |